RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 103-122

  Bobbin, Maggie L ^a   Rossi, John J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Clinical trials; DsiRNA; MiRNA; ShRNA; SiRNA

Indexed keywords

APN 401; ARC 520; BAMOSIRAN; BEVASIRANIB; CASPASE 2; CEQ 508; GENE THERAPY AGENT; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MICRORNA; MRX 34; N ACETYLGALACTOSAMINE; NANOPARTICLE; PATISIRAN; PF 655; PLACEBO; QPI 1007; RANIBIZUMAB; REVUSIRAN; RNA INDUCED SILENCING COMPLEX; RXI 109; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STL 1001; TD 101; TKM 080301; TKM EBOLA; TT 034; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; DRUG;

ADRENAL CORTEX CARCINOMA; ARTICLE; CHRONIC LIVER DISEASE; CONGENITAL PACHYONYCHIA; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL COLON POLYPOSIS; GLAUCOMA; HEMOLYTIC UREMIC SYNDROME; HEMOPHILIA; HEPATIC PORPHYRIA; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; INTRAOCULAR HYPERTENSION; ISCHEMIC OPTIC NEUROPATHY; LIVER CANCER; LIVER CELL CARCINOMA; MACULAR DEGENERATION; NEUROENDOCRINE TUMOR; NONHUMAN; OPEN ANGLE GLAUCOMA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RNA INTERFERENCE; SJOEGREN SYNDROME; TREATMENT OUTCOME; WET MACULAR DEGENERATION; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; PHYSIOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; RNA INTERFERENCE;

EID: 84954099191     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103633     Document Type: Article

References (84)

1. Samaranayake H, Wirth T, Schenkwein D, Raty JK, Yla-Herttuala S. 2009. Challenges in monoclonal antibody-based therapies. Ann. Med. 41:322-31
2. Zamore PD, Tuschl T, Sharp PA, Bartel DP. 2000. RNAi: Double-stranded RNA directs the ATPdependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101:25-33
3. Hannon GJ. 2002. RNA interference. Nature 418:244-51
4. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-11
5. Rettig GR, Behlke MA. 2012. Progress toward in vivo use of siRNAs-II. Mol. Ther. 20:483-512
6. Foged C. 2012. siRNA delivery with lipid-based systems: promises and pitfalls. Curr. Top. Med. Chem. 12:97-107
7. Noland CL, Doudna JA. 2013. Multiple sensors ensure guide strand selection in human RNAi pathways. RNA 19:639-48
8. Snead NM, Rossi JJ. 2012. RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics. Nucleic Acid Ther. 22:139-46
9. Karlsen TA, Brinchmann JE. 2013. Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I. Mol. Ther. 21:1169-81
10. Sui H, ZhouM, Chen Q, Lane HC, Imamichi T. 2014. siRNA enhances DNA-mediated interferon 1 response through crosstalk between RIG-I and IFI16 signalling pathway. Nucleic Acids Res. 42:583-98
11. Christensen J, Litherland K, Faller T, van de Kerkhof E, Natt F, et al. 2014. Biodistribution and metabolism studies of lipid nanoparticle-formulated internally [3H]-labeled siRNA in mice. Drug Metab. Dispos. 42:431-40
12. Nair JK,Willoughby JLS,ChanA,Charisse K, AlamMR,et al. 2014. MultivalentN-acetylgalactosamineconjugated siRNAlocalizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136:16958-61
13. Kanasty R, Dorkin JR, Vegas A, Anderson D. 2013. Delivery materials for siRNA therapeutics. Nat. Mater. 12:967-77
14. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. 2014. RNAi therapies: drugging the undruggable. Sci. Trans. Med. 6:240ps7
15. Arrowhead Res. Corp. 2015. ARC-AAT. http://www. Arrowheadresearch. com/programs/arc-aat
16. Morjaria R, Chong NV. 2014. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema. Expert Opin. Drug Metab. Toxicol. 10:1185-92
17. Thakur A, Fitzpatrick S, Zaman A, Kugathasan K, Muirhead B, et al. 2012. Strategies for ocular siRNA delivery: potential and limitations of non-viral nanocarriers. J. Biol. Eng. 6:7
18. Garba AO, Mousa SA. 2010. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol. Eye Dis. 2:75-83
19. Sylentis. 2013. Zeltia announces that subsidiary Sylentis has commenced Phase II clinical trials with its compound SYL1001 for treating eye discomfort associated with dry eye syndrome. News Release, Febr. 27. http://www. sylentis. com/index. php/en/healthcare-professional-news/54-zeltia-informa-que-sufilial-sylentis-inicia-la-fase-ii-de-ensayos-clinicos-con-su-compuesto-syl1001-para-el-tratamiento-del-dolor-ocular-asociado-al-sindrome-del-ojo-seco. html
20. Colligris B, Alkozi HA, Pintor J. 2014. Recent developments on dry eye disease treatment compounds. Saudi J. Ophthalmol. 28:19-30
21. Gonzalez V, Moreno-Monta ñés J, Sádaba B, Ruz V, Jmenez AI. SYL1001 for treatment of ocular discomfort in dry eye: safety and tolerance (Phase I study). Investig. Ophthalmol. Vis. Sci. 53:575 (Abstr.)
22. Martinez T, GonzalezMV, Roehl I,WrightN, Paneda C, Jimenez AI. 2014. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol. Ther. 22:81-91
23. Quark. 2015. PF-655. http://quarkpharma. com/page-id=28
24. PR Newswire. 2011. In a Phase 2 Study PF-04523655 (RTP801I-14) showed improved vision over standard of care in patients with diabetic macular edema at 12months. News Release,Mar. 18. http://www. prnewswire. com/news-releases/in-a-phase-2-study-pf-04523655-rtp801i-14-showed-improved-vision-overstandard-of-care-in-patients-with-diabetic-macular-edema-at-12-months-118269674. html
25. Quark. 2015. QPI-1007. http://quarkpharma. com/?page-id=23
26. Quark. 2014. Quark announces first patient dosed in a Phase IIa trial evaluating QPI-1007 for neuroprotection in patients with acute primary angle closure glaucoma. News Release, June 25. http://globenewswire. com/news-release/2014/06/25/646585/10087108/en/Quark-Announces-First-Patient-Dosedin-a-Phase-IIa-Trial-Evaluating-QPI-1007-for-Neuroprotection-in-Patients-With-Acute-Primary-Angle-Closure-Glaucoma. html
27. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, et al. 2014. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, Phase 1 trial. Lancet 383:60-68
28. Alnylam. 2015. Hemophilia. http://www. Alnylam. com/product-pipeline/hemophilia/
29. Alnylam. 2015. Alnylam reports initial evidence for potential correction of the hemophilia phenotype in Phase 1 study of ALN-AT3, a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia. News Release, Jan. 11. http://investors. Alnylam. com/releasedetail. cfm?ReleaseID=890625
30. Yasuda M, Gan L, Chen B, Kadirvel S, Yu C, et al. 2014. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. PNAS 111:7777-82
31. Alnylam. 2015. Porphyria. http://www. Alnylam. com/product-pipeline/porphyria/
32. Alnylam. 2015. Complement-mediated disease. http://www. Alnylam. com/product-pipeline/complement-mediated-disease/
33. Borodovsky A, Yuclus K, Sprague A, Banda NK, Holers VM, et al. 2014. ALN-CC5, an investigational RNAi therapeutic targeting C5 for complement inhibition. Proc. Am. Soc. Hematol., San Francisco, CA, 2014. http://www. Alnylam. com/web/assets/ALN-CC5-ASH-Dec2014-panel-by-panel. pdf
34. Alnylam. 2015. TTR amyloidosis (FAP). http://www. Alnylam. com/product-pipeline/ttr-amyloidosisfap/
35. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, et al. 2013. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369:819-29
36. Alnylam. 2014. Alnylam reports six-month clinical data from patisiran Phase 2 open-label extension (OLE) study in patients with familial amyloidotic polyneuropathy (FAP). News Release, Oct. 13. http://investors. Alnylam. com/releasedetail. cfm?ReleaseID=875724
37. Alnylam. 2015. TTR amyloidosis (FAC). http://www. Alnylam. com/product-pipeline/ttr-amyloidosisfac/
38. Snead NM, Escamilla-Powers JR, Rossi JJ, McCaffrey AP. 2013. 5 unlocked nucleic acid modification improves siRNA targeting. Mol. Ther. Nucleic Acids 2:e103
39. Laursen MB, Pakula MM, Gao S, Fluiter K, Mook OR, et al. 2010. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. Biosyst. 6:862-70
40. Nitto Denko. 2013. Leadership in fibrosis. http://www. ndtcorp. com/page/leadership-in-fibrosis
41. Nitto Denko. 2014. New anti-fibrosis drug with molecular targeting DDS completed Phase-1a dose escalation. News Release, Apr. 22. http://www. nitto. com/jp/en/press/2014/0422. jsp
42. Aihara H, Kumar N, Thompson CC. 2014. Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis: rationale and update. Eur. J. Gastroenterol. Hepatol. 26:255-62
43. Steinbach G, Courvalin P, Fruehauf J, SilvaA. 2014. Phase I protocol:CEQ508 in FAPCEQ508. FAP. 01. http://osp. od. nih. gov/sites/default/files/989-Steinbach-cln. pdf
44. Marina Biotech. 2015. Marina Biotech provides 2014 year-end financials and update. News Release, Febr. 25. http://www. marinabio. com/files/2414/2483/8505/15-02-25-Marina-Biotech-Provides-2014 Year-End-Financials-and-Update. pdf
45. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, et al. 2010. First-in-human mutation-targeted siRNA Phase Ib trial of an inherited skin disorder. Mol. Ther. 18:442-46
46. Pachyonychia Congenita Project. 2013. Clinical trials and studies. http://www. pachyonychia. org/clinical-trials-studies. php
47. RXi Pharmaceuticals. 2015. RXI-109. http://www. rxipharma. com/rxi-109/
48. RXi. 2014. RXi Pharmaceuticals announces sustained effect of RXI-109 at three months post scar revision surgery and the completion of enrollment for its Phase 2a trial RXI-109-1301. News Release, Dec. 17. http://www. prnewswire. com/news-releases/rxi-pharmaceuticals-announces-sustained-effect-of-rxi-109-at-three-months-post-scar-revision-surgery-and-the-completion-of-enrollment-forits-phase-2a-trial-rxi-109-1301-300010991. html
49. Apeiron Biologics. 2014. APN401 (Cbl-b). http://www. Apeiron-biologics. com/index. php/projects/apn401-cbl-b. html
50. Salzberg MO, Lametschwandtner G, Schuster M, Loibner H, Sachet M, et al. 2014. Development of a personalized cellular ex-vivo CBL-b silencing cancer immune therapy. Proc. 2014 ASCO Annu. Meet., Chicago, IL
51. Apeiron. 2015. Apeiron announces start of a Phase I trial with a unique cellular anti cancer therapy triggering immunological checkpoint blockade. News Release, Febr. 26. http://prd. At/en/newsroom-clients/apeironannounces-start-of-a-phase-i-trial-with-a-unique-cellular-anti-cancer-therapy-triggeringimmunological-checkpoint-blockade/
52. Nemunaitis J, Barve M, Orr D, Kuhn J, Magee M, et al. 2014. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG)in advanced cancer of the liver. Oncology 87:21-29
53. Gradalis, Inc. 2013. FANGTM personalized tumor vaccine stimulates immune response and more than doubles time to recurrence in patients with advanced stage ovarian cancer. News Release, May 15. http://www. prnewswire. com/news-releases/fang-personalized-tumor-vaccine-stimulates-immune-responseand-more-than-doubles-time-to-recurrence-in-patients-with-advanced-stage-ovarian-cancer-207530021. html
54. Agostini M, Knight RA. 2014. miR-34: from bench to bedside. Oncotarget 5:872-81
55. Arbutus. 2015. TKM-PLK1. http://arbutusbio. com/portfolio/tkm-plk1. php
56. Arbutus. 2014. Tekmira provides update on TKM-PLK1 Phase I/II clinical study in patients with advanced gastrointestinal neuroendocrine tumors and adrenocortical carcinoma. News Release, Dec. 31. http://globenewswire. com/news-release/2014/12/31/694562/10113745/en/Tekmira-Provides-Update-on-TKM-PLK1-Phase-I-II-Clinical-Study-in-Patients-With-Advanced-Gastrointestinal-Neuroendocrine-Tumors-and-Adrenocortical-Carcinoma. html
57. Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, et al. 2010. Enhanced target gene knockdown by a bifunctional shRNA: A novel approach of RNA interference. Cancer Gene Ther. 17:780-91
58. Gorovets D, Saif MW, Huber K. 2014. Novel treatment approaches for locally advanced pancreatic cancer. J. Pancreas 15:95-98
59. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, et al. 2013. Mutant KRAS is a druggable target for pancreatic cancer. PNAS 110:20723-28
60. Golan T, Hubert A, Shemi A, Segal A,Dancour A, et al. 2013. A Phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma. J. Clin. Oncol. 31(Suppl.):4037 (Abstr.)
61. Silenseed. 2015. Pipeline: pancreatic cancer. http://silenseed. com/?page-id=2539
62. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, et al. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910-18
63. ShenH, Rodriguez-Aguayo C, Xu R,Gonzalez-Villasana V,Mai J, et al. 2013. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin. Cancer Res. 19:1806-15
64. Macron D. 2013. MD Anderson team preps for Phase I testing of RNAi cancer drug. Genome Web. https://www. genomeweb. com/rnai/md-anderson-team-preps-phase-i-testing-rnai-cancer-drug
65. Dicerna. 2015. Dicerna Pharmaceuticals announces first patient dosed in Phase 1b/2 clinical trial of DCR-MYC, an investigational RNAi therapeutic targeting the MYC oncogene, in patients with advanced hepatocellular carcinoma. News Release, Febr. 2. http://investors. dicerna. com/releasedetail. cfm?releaseid=893991
66. Dicerna. 2014. DCR-MYC and theMYC oncogene. http://dicerna. com/pipeline/genetic-oncology/dcrmyc-and-the-myc-oncogene/
67. Crema A, Ponzetto A, Clementi M, Carloni G. 2015. Steps and routes of HCV infection: The great promise of new anti-viral targets. Curr. Drug Targets 16(7):757-70
68. Benitec Biopharma. 2015. In-house programs detail: 1. Hepatitis C. http://www. benitec. com/pipeline/in-house-programs-detail#hepc
69. Gebbing M, Bergmann T, Schulz E, Ehrhardt A. 2015. Gene therapeutic approaches to inhibit hepatitis B virus replication. World J. Hepatol. 7:150-64
70. Arbutus. 2015. TKM-HBV. http://arbutusbio. com/portfolio/tkm-hbv. php
71. Wooddell CI, RozemaDB, Hossbach M, John M, Hamilton HL, et al. 2013. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21:973-85
72. Arrowhead Research. 2015. ARC-520. http://www. Arrowheadresearch. com/programs/ARC-520
73. Pol S, Lampertico P. 2012. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J. Viral Hepatitis 19:377-86
74. Arrowhead Research. 2014. Arrowhead files IND for RNAi therapeutic ARC-520 to begin Phase 2b multipledose studies in chronic hepatitis B patients. News Release, Dec. 15. http://ir. Arrowheadresearch. com/releasedetail. cfm?releaseid=887586
75. Arrowhead Research. 2015. Arrowhead provides update on IND for ARC-520 Phase 2b study. News Release, Jan. 12. http://ir. Arrowheadresearch. com/releasedetail. cfm?releaseid=890676
76. Arrowhead Research. 2014. Arrowhead presents data on ARC-520 and ARC-AAT at AASLD The Liver MeetingR 2014. News Release, Nov. 10. http://ir. Arrowheadresearch. com/releasedetail. cfm?releaseid=881791
77. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, et al. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375:1896-905
78. Haussecker D. 2014. Developing aerosolized TKM-EBOLA as airborne transmission of Ebola likely.
79. Arbutus. 2015. Tekmira initiates Phase I clinical trial of TKM-HBV. News Release, Jan. 21. http://www. sec. gov/Archives/edgar/data/1447028/000117184315000285/newsrelease. htm
80. Dicerna. 2015. EMA grants orphan drug designation to DCR-PH1, Dicerna's investigational therapy for the treatment of primary hyperoxaluria type 1 (PH1). News Release, Aug. 6. http://www. businesswire. com/news/home/20150806006411/en/EMA-Grants-Orphan-Drug-Designation-DCR-PH1-Dicernas#. VgWExN9VhBc
81. Alnylam. 2015. Alnylam files clinical trial application (CTA) forALN-AAT, an investigational RNAi therapeutic for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (alpha-1 liver disease). News Release, May 17. http://investors. Alnylam. com/releasedetail. cfm?ReleaseID=913507
82. Arbutus. 2015. Tekmira provides corporate update and announces year-end 2014 results. News Release, Mar. 12 http://investor. Arbutusbio. com/releasedetail. cfm?ReleaseID=901392
83. Thi EP, Mire CE, Lee ACH, Geisbert JB, Zhou JZ, et al. 2015. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521:362-65
84. Arbutus. 2015. TKM-Ebola-Guinea enters Phase II clinical study in Sierra Leone. News Release, Mar. 11. http://investor. Arbutusbio. com/releasedetail. cfm?ReleaseID=901104